Home Cart Sign in  
Chemical Structure| 39011-92-2 Chemical Structure| 39011-92-2

Structure of Specnuezhenide
CAS No.: 39011-92-2

Chemical Structure| 39011-92-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nuezhenide is a naturally occuring iridoid possessing restraint of hypoxia-induced retinal angiogenesis effect.

Synonyms: Nuezhenide; (8E)-Nuezhenide; Nuzhenide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Specnuezhenide

CAS No. :39011-92-2
Formula : C12H22O2
M.W : 686.66
SMILES Code : O=C(C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C([C@@H]1CC(OC[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCC4=CC=C(O)C=C4)O3)=O)=C/C)OC
Synonyms :
Nuezhenide; (8E)-Nuezhenide; Nuzhenide
MDL No. :MFCD20274720

Safety of Specnuezhenide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Specnuezhenide

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Colon 26 cell line 10 mg/mL 0, 1, 2, 6, 12, 24 hours To investigate the metabolic characteristics of SNZ in gut microbiota, it was found that SNZ was completely metabolized within 1 hour. J Pharm Anal. 2023 Sep;13(9):1024-1040
Colon 26 colorectal cancer cells 10 mg/mL 0, 15, 30, 60, 90, 120 min To investigate the metabolic characteristics of SNZ by gut microbiota, SNZ was rapidly metabolized to salidroside and tyrosol. J Pharm Anal. 2023 Sep;13(9):1024-1040
Liver microsomes and liver homogenate 1 mM 0, 15, 30, 60, 90, 120 minutes To study the metabolic characteristics of SNZ in the liver, it was found that SNZ had very weak metabolic ability in the liver. J Pharm Anal. 2023 Sep;13(9):1024-1040
Rat chondrocytes 0, 10, 50, 100, 200 µM 24 and 48 hours To evaluate the effect of SPN on rat chondrocyte viability, results showed no significant cytotoxicity at concentrations of 0–200 μM. Front Pharmacol. 2018 Jun 28;9:700
RAW264.7 cells 0, 50, 100, 200 µM 24 hours To evaluate the effect of SPN on LPS-induced inflammation, results showed SPN significantly down-regulated the mRNA and protein levels of iNOS and COX2. Front Pharmacol. 2018 Jun 28;9:700
Rat chondrocytes 0, 10, 50, 100, 200 µM 24 hours To evaluate the effect of SPN on IL-1β-induced chondrocyte-specific gene degradation and cartilage matrix-degrading enzyme expression, results showed SPN down-regulated the expression of MMP3, MMP9, IL-6, iNOS, and COX2. Front Pharmacol. 2018 Jun 28;9:700
RAW264.7 cells 10−1 µM 48 hours SPN inhibited osteoclast differentiation of RAW264.7 cells by activating the TGR5/FXR pathway. Drug Des Devel Ther. 2025 Mar 6;19:1595-1608.
Bone marrow mesenchymal stem cells (BMSCs) 10−1 µM 48 hours SPN inhibited BMSCs senescence and promoted osteogenic differentiation by activating the TGR5/FXR pathway. Drug Des Devel Ther. 2025 Mar 6;19:1595-1608.
Rat chondrocytes 0, 50, 100, 200 µM 48 hours To evaluate the effect of SPN on IL-1β-induced chondrocyte-specific gene degradation and cartilage matrix-degrading enzyme protein levels, results showed SPN significantly decreased the protein levels of MMP3, MMP9, IL-6, and iNOS, and increased the protein levels of collagen II and sox9. Front Pharmacol. 2018 Jun 28;9:700
Human acute retinal pigment epithelial-19 (ARPE-19) cells 0.2, 1.0 and 5.0 μg/mL 48 hours SPN inhibited VEGFA secretion by ARPE-19 cells under hypoxia condition, down-regulated the mRNA expressions of VEGFA and PHD-2 slightly, and the protein expressions of VEGFA, HIF-1α and PHD-2 significantly in vitro. Molecules. 2016 Dec 21;21(12):1756
Bone marrow macrophages (BMMs) 0, 10, 50, 200 µM 5 days Inhibited RANKL-induced osteoclast formation, reduced the number of TRAP-positive multinucleated cells Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1080-1089

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c mice Colorectal tumor model Oral 109.2 mg/kg Continuous administration for 10 days To evaluate the therapeutic effect of SNZ on colorectal tumors, SNZ significantly inhibited tumor growth and modulated the gut microbiota structure. J Pharm Anal. 2023 Sep;13(9):1024-1040
Balb/c mice Colorectal tumor model Oral administration 109.2 mg/kg Continuous administration for 10 days To investigate the therapeutic effect of SNZ on colorectal tumors, it was found that SNZ significantly inhibited tumor growth and modulated the structure of gut microbiota. J Pharm Anal. 2023 Sep;13(9):1024-1040
Sprague-Dawley rats OA model induced by surgical excision of ACL and MM Intra-articular injection 200 μM, 0.14 mg/kg Every 7 days for 8 weeks To evaluate the effect of SPN on a rat model of OA, results showed SPN treatment significantly reduced cartilage degeneration and inflammatory factor levels, and improved subchondral bone microstructure. Front Pharmacol. 2018 Jun 28;9:700
ICR mice D-galactose-induced aging mouse model Oral gavage 5 mg/kg/d and 10 mg/kg/d Once daily for 12 weeks SPN attenuated D-gal-induced hepatic lipid accumulation and inflammation by modulating bile acid homeostasis and gut microbiota to improve liver function. Metabolites. 2023 Aug 18;13(8):960
ICR mice D-galactose-induced senile osteoporosis model Oral gavage 5 mg/kg/d, 10 mg/kg/d Once daily for three months SPN improved D-galactose-induced osteoporosis in mice by activating the TGR5/FXR pathway, increasing bone mineral density and trabecular number. Drug Des Devel Ther. 2025 Mar 6;19:1595-1608.
Sprague Dawley (SD) rats Oxygen-induced retinopathy (OIR) model Intraperitoneal injection 5.0 and 10.0 mg/kg Administration started on postnatal day 12 and lasted for 5 days SPN prevented hypoxia-induced retinal neovascularization in an 80% oxygen atmosphere, significantly reducing retinal avascular areas. Molecules. 2016 Dec 21;21(12):1756
Sprague-Dawley (SD) rats Diabetic osteoporosis model Intraarticular injection 50 μM (0.035 mg/kg), 200 μM (0.14 mg/kg) Every 7 days for 6 weeks Suppressed diabetes-induced bone loss, reduced the number of osteoclasts, regulated bone metabolism markers Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1080-1089

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.46mL

0.29mL

0.15mL

7.28mL

1.46mL

0.73mL

14.56mL

2.91mL

1.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories